Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Kuangli Bio-Tech Holdings Co. Ltd. (6431:TWSE), powered by AI.
Kuangli Bio-Tech Holdings Co. Ltd. is currently trading at $16.30. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Kuangli Bio-Tech Holdings Co. Ltd. on Alpha Lenz.
Kuangli Bio-Tech Holdings Co. Ltd.'s P/E ratio is -7.9.
“Kuangli Bio-Tech Holdings Co. Ltd. trades at a P/E of -7.9 (undervalued) with modest ROE of -37.2%.”
Ask for details →Kuangli Bio-Tech Holdings Co. Ltd. is a company engaged in the biotechnology sector, focusing on the research, development, and production of health-related products. It plays a significant role in the life sciences industry, offering a portfolio that spans across pharmaceuticals, nutraceuticals, and various bioactive compounds. Kuangli Bio-Tech's primary function is to enhance health and wellness through innovative biotechnology solutions. The company’s products often impact sectors such as healthcare, agriculture, and environmental sciences, demonstrating versatility and adaptability in meeting diverse industry needs. In the financial market, Kuangli Bio-Tech Holdings Co. Ltd. stands out as a dynamic player capitalizing on the growing demand for biotechnology-based advancements. By investing in cutting-edge research and development, the company contributes to the development of new solutions aimed at addressing global health challenges, thus holding a strong position within the biotechnology landscape.
“Kuangli Bio-Tech Holdings Co. Ltd. trades at a P/E of -7.9 (undervalued) with modest ROE of -37.2%.”
Ask for details →Kuangli Bio-Tech Holdings Co. Ltd. (ticker: 6431) is a company listed on TWSE in the Consumer Defensive sector (Household & Personal Products). Market cap is $1.5B.
The current price is 16.3 with a P/E ratio of -7.86x and P/B of 2.63x.
ROE is -37.21% and operating margin is -39.42%. Annual revenue is $377M.